Table 1

Summary of the included possible risk factors

DemographicalGender (male)
Age (>65 years)
ClinicalAdvanced binet stage (B/C)
CLL-IPI score (>1)
B-symptoms (unintentional weight loss, extensive tiredness, fever (>38.0℃), night sweats)
Lymphadenopathy (size (diagonal measure, cm), number of lymph nodes and number of nodal areas)
Splenomegaly (>12 cm)
ECOG-PS (>1)
Smoking status (yes/no)
Comorbidities (CIRS and CCI)
Genetic/BiologicalDel(13q) absence, normal FISH
Tri12
Del(11q)
Del(17 p)
TP53 mutation status
CDKN2A and NOTCH1 mutation status
Unmutated IGHV status (≥98 germline identity)
CD38, CD49d, ZAP-70 positivity (Population > 30% positive)
Ki-76, C-MYC, PAX-5, BcL-2, Bcl-6, CD79-a, MUM-1 positivity on pathology samples following RT
DLBCL subtype (GCB or ABC)
Biochemical21 Haemoglobin (<10 g/dl)
Platelet count (<100×109/L)
Peripheral blood leucocytes (>8,8 109/ L)
Peripheral blood lymphocytes (5×109/ L)
Peripheral blood neutrophils (<2.25×109/L)
β−2-microglobulin elevation (>4 mg/L ng/mL)
Lactate dehydrogenase elevation (>205 U/L)
Abnormal levels of immunoglobulins (IgM, IgG, IgA)
Treatment-relatedCLL-treatment regimens
Chemoimmunotherapy (purine-nucleoside analogue and/or alkylating agents plus/minus monoclonal antibody therapy and/or kinase inhibitor therapy)
Stem cell transplantation
Radiation therapy
RT-treatment regimens
Chemoimmunotherapy (purine-nucleoside analogue and/or alkylating agents plus/minus monoclonal antibody therapy and/or kinase inhibitor therapy)
Stem cell transplantation
Radiation therapy
  • ABC, activated B-cell-like; CCI, Charlson Comorbidity Scoring System; CDKN2A, cyclin-dependednt kinase Inhibitor 2A; CD38, cluster of differentiation 38; CD79-a, cluster of differentiation 79; CIRS, Cumulative Illness Rating Scale; CLL, chronic lymphocytic leukemia; CLL-IPI, International Prognostic Index of CLL; DLBCL, diffuse large B-cell lymphoma; ECOG, Eastern Cooperative Oncology Group Performance Status (ECOG-PS); FISH, Fluorescende In Situ Hybridization; GCB, Germinal center B-cell-like; MUM-1, multiple myeloma oncogene 1 NOTCH1, neurogenic locus notch homolog protein 1; PAX-5, paired box protein 5; RT, Richter’s Transformation; TP53, tumor protein p53; ZAP-70, zeta-chain-associated protein kinase 70.